Grant Support

 

 

Grant/Contract #

Duration of Grant/Contract

Total UCSD Direct Dollars

NIH (Spector, Stephen)
2 UM1 AI069536-08
 
​12/1/2013 – 11/30/2020
HIV Centers for Underrepresented Populations in Research CTU (HIV CURE CTU)
The major goals of this project are to develop improved methods for the treatment of HIV-infected children, youth (through age 24 years) and underrepresented adult populations, the evaluation of candidate HIV vaccines, the prevention of HIV mother-to-child transmission and the development of strategies for the cure of HIV infection.
​$ 1,865.451
​NIH/Harvard (Seage, George; Spector, Stephen PI UCSD)
U01 AI068632

​09/03/2010 – 7/31/2015
Pediatric HIV/AIDS Cohort Study Initiative (SMARTT Study)
As part of the SMARTT study, the UCSD-MCAHP contributes to the assessment of growth, cardiac toxicity, neurodevelopment, speech, language and hearing in HIV uninfected children born to HIV-infected pregnant women exposed in utero and in the newborn period to antiretrovirals.  

​$393,182
​NIH/Harvard (Seage, George; Spector, Stephen PI UCSD) 
U01 AI068632
​09/03/2010 – 7/31/2015
As part of the AMP study, the UCSD-MCAHP contributes to defining the long-term impact of HIV infection and antiretroviral therapy on growth and development, sexual maturation, pubertal development, and cognitive, academic, vocational and social development of preadolescents and adolescents with perinatal HIV infection
​$421,600
​5 H12 HA24781-02 (Spector, Stephen) 
PHS HRSA
​08/01/2012- 07/31/2015

Ryan White IV Women, Infants, Children, Youth and Affected Family Members AIDS Healthcare
The UCSD Mother-Child-Adolescent HIV Program (UCSD-MCAHP) system of coordinated WICY care will improve access to comprehensive and coordinated ambulatory HIV medical care and support services, optimize health outcomes, prevent new infections and reduce HIV related health disparities.
​ $ 1,192,968
​90CB0178/01 (Spector, Stephen) DHHS Administration for Children and Families        09/30/2012 – 9/29/2016
         

Families Affected by Substance Abuse and/or HIV AIDS
We will identify and address the needs of those infants and children who are or might be abandoned and develop an integrated model. We will collaborate and train health and social service personnel, to meet the needs of the abandoned or at risk children.
​$ 736,250
​1 UM1AI10676-01 (Aldrovandi, Grace; Spector, Stephen PI UCSD)
NIH/Children’s Hospital Los Angeles
​12/01/2013 – 11/30/2020
IMPAACT Network Immunogenetics Specialty Laboratory
The objectives of this research are to provide immunologic assessment of children and adolescents participating in clinical trials and to develop new assays designed to monitor the immunopathogenesis of
HIV in pregnant women, children and youth participating in IMPAACT Network clinical trials.
​$146,286
​5UO1HD052104-09 (VanDyke, Russell, Spector, Stephen PI UCSD)

NIH/Tulane University           

​08/01/2013 – 07/31/2015
These funds are provided to identify the continental ancestry of subjects participating in the PHACS AMP and SMARTT protocols, and to apply these findings as a covariate when evaluating clinical outcomes.
​$ 313,100
1 R01 NS084912-01 (Spector, Stephen) 5/1/13 – 4/30/2018
NIH/NINDS
​Modulating Autophagy to Eradicate HIV-1 from CNS Reservoirs

This research examines the role of autophagy in the preservation of HIV reservoirs within the central nervous system and in order to identify strategies to eradicate virus from these occult sites.  This research will build upon our considerable preliminary data that has established autophagy as an important mechanism of HIV pathogenesis with the goal of inducing autophagy as a mechanism to inhibit HIV and preferentially kill HIV infected cells

​$388,950

TR701-111 (Bradley, PI)

Trius Pharmaceuticals

03/01/2010 – 03/31/2013

A Phase 1, Open-Label, Multi-Center, Two-Part, Single-Dose, Parallel-Design, Safety, Tolerance, and Pharmacokinetic Study of Orally and Intravenously Administered TR-701-FA in 12 to 17 Year Old Adolescent Patients

$78,000

NP25138 (Bradley, PI)

Roche

02/01/2010 – 01/31/2013

An open label, prospective, pharmacokinetic /pharmacodynamics and safety evaluation of intravenous oseltamivir (Tamiflu®) in the treatment of infants less than one year of age with influenza infection

$16,500

DAP-PEDS-09-01 (Bradley, PI)

Cubist Pharmaceuticals

03/01/2010 – 11/30/2012

An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged Three Months to Twenty-Four Months Who are Concurrently Receiving Standard Antibiotic Therapy for Proven or Suspected Gram-positive Infection

$61,500

TR701-113 (Bradley, PI)

Trius Pharmaceuticals

11/01/2012 – Current

A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous to Oral 6-Day TR-701 Free Acid and Intravenous to Oral 10 Day Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

 

Protocol DAP-PEDS-07-03 (Bradley, PI)

Cubist Pharmaceuticals

07/01/2009 – Current

An Evaluation of the Safety, Efficacy and Pharmacokinetics of Daptomycin in Pediatric Subjects Aged One to Seventeen Years With Complicated Skin and Skin Structure Infections Caused by Gram-Positive Pathogens

$600,000

BAY 12-8039/ 11826 (Bradley, PI)

Bayer Healthcare Pharmaceuticals Inc.

04/01/2010 – Current

Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients

$125,000

(NAI113678) (Bradley) (GlaxoSmithKline

10/01/2010 – Current 

An Open-Label, Multi-Center, Single Arm Study to Evaluate the Safety and Tolerability of Intravenous Zanamivir in the Treatment of Hospitalized Adult, Adolescent and Pediatric Subjects with Confirmed Influenza Infection

$100,000

6096A1-4024-US (B1851040) (Bradley, PI) Pfizer, Inc.

11/01/2010 – Current

Postmarketing observational study of the impact of prevnar 13 (pneumococcal 13-valent conjugate vaccine) on otitis media in children

$25,000

P03579 (Bradley, PI) Merck & Co

01/01/2011 – Current

Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children with Neutropenia

$150,000

U54HD071600 (Bradley, PI) NIH

09/26/2011 – 06/ 30/2016

Colistimethate Single Dose Pharmacokinetics in Infants and Children

$278,550

U54HD071600 (Bradley, PI) NIH

09/26/2011 – 06/30/2016

Plasma and Intracellular Cathelicidin Responses to Infection in Infants and Young Children

$90,000

DAP-PEDBAC-11-02 (Bradley, PI)

Cubist Pharmaceuticals

01/01/2013 - Current

A Comparative Evaluation of the Safety, Efficacy and Pharmacokinetics of Daptomycin with Standard of Care in Pediatric Subjects 2 - 17 Years of Age With Bacteremia caused by Staphylococcus aureus

Study initiated

D4280C00014 (Bradley, PI)  AstraZeneca

06/01/2013 – Current

 A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection

$75,000

DAP-PEDOST-011-03 (Bradley, PI)

Cubist Pharmaceuticals

09/01/2013 – Current

A Multicenter, Randomized, Double-Blinded Comparative Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daptomycin Versus Active Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis Due to Gram-Positive Organisms

Study initiated

DUR001-106 (Bradley, PI) Durata Therapeutics, International B.V.

09/01/2013 – Current 

A phase 1, open label, single dose study to investigate the Pharmacokinetics, safety and tolerability of dalbavancin in hospitalized children aged 3 months to 11 years receiving standard intravenous anti-infective treatment for bacterial infections

Study initiated

P903-21 (Cannavino, PI) Cerexa, Inc.

03/01/2011 – 06/30/2013

Pharmacokinetics of a Single Dose of Ceftaroline fosamil in Children Ages Birth to Younger than 12 Years with Suspected or Confirmed Systemic Infection

$38,000

P903-23 (Cannavino, PI) Cerexa, Inc.

10/01/2011 – Current 

A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Ceftaroline Versus Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections

$150,000

DORIPED3001 (Cannavino, PI)

Johnson & Johnson

08/01/2012 – Current 

A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Meropenem in Hospitalized Children With Complicated Intra-abdominal Infections

$150,000

P903-31(Cannavino, PI) Cerexa, Inc.

11/01/2012 – Current

 A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone in Pediatric Subjects With Community-acquired Bacterial Pneumonia Requiring Hospitalization. Cerexa Protocol

$150,000

P903-24 (Cannavino, PI) Cerexa, Inc.

01/01/2013 – Current 

A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone Plus Vancomycin in Pediatric Subjects With Complicated Community-acquired Bacterial Pneumonia

$150,000

RCHSD Contract #11774 (Leake) Baylor College of Medicine

2001 – Current 

United States Multicenter Pediatric Meningococcal Surveillance Study

$3,000

Grant # AI103315-01 (Pong, PI) NIH RO1

01/01/2012 – Current

Retrospective Chart Reviews for the Pediatric Fungal Network

$5,000

HHSN272200900044C (Pong, PI)

La Jolla Institute for Allergy and Immunology/NIH

01/01/2013 – Current

Identification of HLA Class II T Cell Epitopes from Mycobacterium bovis

$12,283